Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer

Motterle, Giovanni; Andrews, Jack R.; Morlacco, Alessandro; Karnes, R. Jeffrey

doi:10.1016/j.euf.2019.10.016

Cited by 48 publications

(32 citation statements)

References 72 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neoadjuvant chemotherapy has been recommended prior to radical cystectomy for bladder cancer. Although the survival benefit is nearly 5–10%, some subjects cannot respond to chemotherapy 28 . Thus, identifying predictors may distinctly reduce side effects and miss the optimal time for surgery.…”

Section: Discussionmentioning

confidence: 99%

An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer

Hou

Liang

Xie

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) participate in cancer immunity. We characterized the clinical significance of an immune-related lncRNA model and evaluated its association with immune infiltrations and chemosensitivity in bladder cancer. Transcriptome data of bladder cancer specimens were employed from The Cancer Genome Atlas. Dysregulated immune-related lncRNAs were screened via Pearson correlation and differential expression analyses, followed by recognition of lncRNA pairs. Then, a LASSO regression model was constructed, and receiver operator characteristic curves of one-, three- and five-year survival were established. Akaike information criterion (AIC) value of one-year survival was determined as the cutoff of high- and low-risk subgroups. The differences in survival, clinical features, immune cell infiltrations and chemosensitivity were compared between subgroups. Totally, 90 immune-related lncRNA pairs were identified, 15 of which were screened for constructing the prognostic model. The area under the curves of one-, three- and five-year survival were 0.806, 0.825 and 0.828, confirming the favorable predictive performance of this model. According to the AIC value, we clustered patients into high- and low-risk subgroups. High-risk score indicated unfavorable outcomes. The risk model was related to survival status, age, stage and TNM. Compared with conventional clinicopathological characteristics, the risk model displayed higher predictive efficacy and served as an independent predictor. Also, it could well characterize immune cell infiltration landscape and predict immune checkpoint expression and sensitivity to cisplatin and methotrexate. Collectively, the model conducted by paring immune-related lncRNAs regardless of expressions exhibits a favorable efficacy in predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer

Hou

Liang

Xie

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Bladder cancer is a complex malignant tumor, and chemotherapy is one of its essential treatment options. The guidelines recommend neoadjuvant chemotherapy before radical cystectomy of patients with BLCA, and the survival benefit of patients is close to 5-10%; nevertheless, some patients still do not respond to chemotherapy (48). Therefore, identifying predictors can avoid missing the optimal timing of surgery and minimize the adverse effects of chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

A Necroptosis-Related lncRNA to Develop a Signature to Predict the Outcome, Immune Landscape, and Chemotherapeutic Responses in Bladder Urothelial Carcinoma

Hou

Dong

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveMany studies have drawn their attention to the immunotherapy of bladder urothelial carcinoma in terms of immunologic mechanisms of human body. These include immunogenicity of the tumor cells and involvement of long non-coding RNA (lncRNA). We constructed a necroptosis-related long noncoding RNA (nrlncRNA) risk factor model to predict BLCA outcomes and calculate correlations with chemosensitivity and immune infiltration.MethodsTranscriptomic data from BLCA specimens were accessed from The Cancer Genome Atlas, and nrlncRNAs were identified by performing co-expression analysis. Univariate analysis was performed to identify differentially expressed nrlncRNA pairs. We constructed least absolute contraction and selector operation regression models and drew receiver operating characteristic curves for 1-, 3-, and 5-year survival rates. Akaike information criterion (AIC) values for survival over 1 year were determined as cutoff values in high- and low-risk subgroups. We reassessed the differences between subgroups in terms of survival, clinicopathological characteristics, chemotherapy efficacy, tumor-infiltrating immune cells, and markers of immunosuppression.ResultsWe identified a total of 260 necroptosis-related lncRNA pairs, of which we incorporated 13 into the prognostic model. Areas under the curve of 1-, 3-, and 5- year survival time were 0.763, 0.836, and 0.842, respectively. We confirmed the excellent predictive performance of the risk model. Based on AIC values, we confirmed that the high-risk group was susceptible to unfavorable outcomes. The risk scores correlated with survival were age, clinical stage, grade, and tumor node metastases. The risk model was an independent predictor and demonstrated higher predictive power. The risk model can also be utilized to determine immune cell infiltration status, expression levels of immune checkpoint genes, and the sensitivity to cisplatin, doxorubicin, and methotrexate.ConclusionWe constructed a novel necroptosis-related signature that predicts BLCA outcomes and performs satisfactorily in the immune landscape and chemotherapeutic responses.

show abstract

“…Neoadjuvant chemotherapy has been recommended prior to radical cystectomy for bladder cancer. Although the survival bene t is nearly 5-10%, some subjects cannot respond to chemotherapy 24 . Thus, identifying predictors may distinctly reduce side effects and miss the optimal time for surgery.…”

Section: Discussionmentioning

confidence: 99%

An Immune-Related lncRNA Model for Predicting Prognosis, Immune Landscape and Chemotherapeutic Response in Bladder Cancer

Hou¹,

Liang²,

Xie³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: Long noncoding RNAs (lncRNAs) participate in cancer immunity. Herein, we characterized the clinical significance of immune-related lncRNA model and its associations with immune infiltrations and chemosensitivity in bladder cancer.Methods: Transcriptome data of bladder cancer specimens were employed from The Cancer Genome Atlas. Dysregulated immune-related lncRNAs were screened via Pearson correlation and differential expression analyses, followed by recognition of lncRNA pairs. Then, a LASSO regression model was constructed. Receiver operator characteristic curves of one-, three- and five-year survival were plotted. Akaike information criterion (AIC) value of one-year survival was determined as the cutoff of high- and low-risk subgroups. The differences in survival, clinical features, immune cell infiltrations and chemosensitivity were compared between subgroups.Results: Totally, 90 immune-related lncRNA pairs were selected, 15 of which were put into the prognostic model. The area under the curves of one-, three- and five-year survival were 0.806, 0.825 and 0.828, confirming the favorable predictive performance of this model. According to the AIC value, we clustered subjects into high- and low-risk subgroups. High-risk score indicated unfavorable outcomes. This risk model was in relation to survival status, age, stage and TNM. In comparison to conventional clinicopathological characteristics, the risk model displayed higher predictive efficacy and was an independent predictor. Also, it could well characterize immune cell infiltration landscape and predict immune checkpoint expression and sensitivity to cisplatin and methotrexate.Conclusion: This model conducted by paring immune-related lncRNAs regardless of expressions exhibited a favorable efficacy in predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer.

show abstract

Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer

Cited by 48 publications

References 72 publications

An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer

An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer

A Necroptosis-Related lncRNA to Develop a Signature to Predict the Outcome, Immune Landscape, and Chemotherapeutic Responses in Bladder Urothelial Carcinoma

An Immune-Related lncRNA Model for Predicting Prognosis, Immune Landscape and Chemotherapeutic Response in Bladder Cancer

Contact Info

Product

Resources

About